[Market Movement Analysis] bioAffinity surges on September 17: Hong Kong patent approved + non-invasive lung cancer detection + entry into the Asian market

1. On September 17, the Hong Kong Intellectual Property Department granted the company a patent (HK40048460) for the CyPath® Lung platform, covering systems and methods that utilize antibodies, TCPP, and flow cytometry to analyze sputum cells and determine the presence of lung cancer cells. This technology forms the scientific basis of CyPath® Lung.
2. On September 17, the company stated that CyPath® Lung is its core product for commercialization, used to assess the malignancy risk of pulmonary nodules detected by low-dose CT and incidental imaging findings. In Asia, there are an estimated 1.6 million new cases of lung cancer every year, providing a potential market for non-invasive lung cancer detection.
3. On September 9, the company regained compliance with Nasdaq’s minimum price and warrant-related listing requirements; common stock and warrants will continue to be traded on the Nasdaq Capital Market, and the previously scheduled hearing has been canceled.

(Disclaimer: This content is generated by AI-based summarization of public information and is for reference only. It does not constitute investment advice.)